Halifax, Canada Clinical Trials

A listing of Halifax, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 74 clinical trials
Linaclotide Safety and Efficacy in Pediatric Participants 6 to 17 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

The objective of LIN-MD-64 is to evaluate the safety and efficacy of 12 weeks of linaclotide therapy (72 g daily) in comparison with placebo in pediatric participants, 6 to 17 years of age, who fulfill modified Rome III Criteria for Child/Adolescent Functional Constipation (FC). The objective of LIN-MD-64 is to …

laxative
incontinence
posturing
DSMED
 (10.0 away) Contact site
  • 136 views
  • 26 Sep, 2021
  • +303 other locations
Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer

Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques. SABR is non-invasive and delivered on an outpatient basis. The purpose of this study is to compare the effect of SABR, relative to standard of care (SOC) …

metastasis
positron emission tomography
cancer
bone scan
stereotactic body radiation therapy
Nova Scotia Cancer Centre
 (0.7 away) Contact site
  • 31 views
  • 20 Sep, 2021
  • +10 other locations
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer

NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin, in patients with previously untreated advanced biliary tract cancer. The primary hypotheses are: The combination of NUC-1031 plus cisplatin prolongs overall survival compared to the gemcitabine plus cisplatin standard of care The combination of NUC-1031 plus cisplatin increases overall response …

measurable disease
biliary obstruction
cisplatin/gemcitabine
obstruction
international normalized ratio
Nova Scotia Health Authority
 (0.7 away) Contact site
  • 73 views
  • 24 Sep, 2021
  • +129 other locations
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) and to compare everolimus with respect to overall survival (OS). The hypothesis is …

growth factor
clear cell renal cell carcinoma
everolimus
solid tumour
kinase inhibitor
Nova Scotia Health Authority QEII-HSC ( Site 0150)
 (0.8 away) Contact site
  • 168 views
  • 26 Sep, 2021
  • +182 other locations
A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)

This study is designed to evaluate how the body processes and removes mirikizumab. The study will also evaluate safety and disease response in pediatric participants with UC taking mirikizumab. The study will last about 52 weeks and may include up to 17 visits.

corticosteroids
mirikizumab
janus kinase inhibitor
immunomodulators
IWK Health Centre
 (0.8 away) Contact site
  • 2 views
  • 26 Sep, 2021
  • +42 other locations
This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.

Major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment, either as single agent or in combination with pembrolizumab, in addition to evaluate the MPR rate of pembrolizumab as a single agent. Additionally the dynamics of the tumor microenvironment changes on treatment by comparing pre-, on- and post-treatment …

pembrolizumab
Novartis Investigative Site
 (0.8 away) Contact site
  • 7 views
  • 21 Sep, 2021
  • +44 other locations
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankizumab works compared to ustekinumab. This study will assess change in Crohn's Disease Activity Index (CDAI). Risankizumab is an investigational drug being developed for the treatment of …

tumor necrosis factor
abdominal pain
crohn's disease
risankizumab
ustekinumab
QEII Health Sciences Centre /ID# 223748
 (0.7 away) Contact site
  • 106 views
  • 26 Sep, 2021
  • +483 other locations
Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

Acute Spinal Cord Injury (SCI) is a rare injury that leads to permanent neuromotor impairment and sudden disability. Approximately 25,000 people experience cervical SCI in the United States, Europe, and Japan every year. The purpose of this study is to see if elezanumab is safe and assess change in Upper …

spinal cord
acute spinal cord injury
spinal injury
spinal cord disorder
cervical spinal cord injury
QEII Health Sciences Centre /ID# 215249
 (0.7 away) Contact site
  • 86 views
  • 17 Sep, 2021
  • +54 other locations
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement …

steatohepatitis
hepatic fibrosis
fibrosis
Nova Scotia Health Authority QEII (Queen Elizabeth II) Health Sciences Centre
 (0.8 away) Contact site
  • 72 views
  • 26 Sep, 2021
  • +350 other locations
A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.

This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the efficacy and safety of maternal immunization with RSVpreF against medically attended lower respiratory tract illness (MA-LRTI) in infants.

prenatal
lower respiratory tract infection
vaccination
Canadian Center for Vaccinology - IWK Health Centre
 (1.4 away) Contact site
  • 139 views
  • 26 Sep, 2021
  • +463 other locations